Interactions of oxaloacetate with Escherichia coli fumarate reductase

https://doi.org/10.1016/0003-9861(89)90561-4Get rights and content

Abstract

Fumarate reductase of Escherichia coli is converted to a deactivated state when tightly bound by oxaloacetate (OAA). Incubation of the inhibited enzyme with anions or reduction of the enzyme by substrate restores both the activity of the enzyme and its sensitivity to thiol reagents. In these respects the enzyme behaves like cardiac succinate dehydrogenase. Close to an order of magnitude difference was found to exist between the affinities of OAA for the oxidized (KD ∼ 0.12 μM) and reduced (KD ∼ 0.9 μM) forms of fumarate reductase. Redox titrations of deactivated fumarate reductase preparations have confirmed that reductive activation, as in cardiac succinate dehydrogenase (B. A. C. Ackrell, E. B. Kearney, and D. Edmondson (1975) J. Biol. Chem.250, 7114–7119), is the result of reduction of the covalently bound FAD moiety and not the non-heme iron clusters of the enzyme. However, the processes differed for the two enzymes; activation of fumarate reductase involved 2e and 1H+, consistent with reduction of the flavin to the anionic hydroquinone form, whereas the process requires 2e and 2H+ in cardiac succinate dehydrogenase. The reason for the difference is not known. The redox potential of the FADFADH2 couple in FRD (Em ∼ −55 mV) was also slightly more positive than that in cardiac succinate dehydrogenase (—90 mV).

References (35)

  • G. Cecchini et al.

    J. Biol. Chem

    (1986)
  • J.H. Weiner et al.

    J. Biol. Chem

    (1979)
  • J.E. Morningstar et al.

    J. Biol. Chem

    (1985)
  • M.K. Johnson et al.

    Biochem. Biophys. Res. Commun

    (1985)
  • B.A.C. Ackrell et al.

    J. Biol. Chem

    (1975)
  • T. Ohnishi et al.

    Biochem. Biophys. Res. Commun

    (1973)
  • B.A.C. Ackrell et al.
  • A.D. Vinogradov et al.

    Biochem. Biophys. Res. Commun

    (1972)
  • C.J. Coles et al.

    FEBS Lett

    (1977)
  • A.B. Kotlyar et al.

    Biochim. Biophys. Acta

    (1984)
  • M.L. Baginsky et al.

    J. Biol. Chem

    (1969)
  • P.L. Dutton

    Biochim. Biophys. Acta

    (1971)
  • A.G. Gornall et al.

    J. Biol. Chem

    (1949)
  • J.F. Riordan et al.
  • G. Unden et al.

    Biochim. Biophys. Acta

    (1984)
  • M.K. Johnson et al.

    Biochem. Biophys. Res. Commun

    (1985)
  • B.A.C. Ackrell et al.

    J. Biol. Chem

    (1980)
  • Cited by (42)

    • Modular structure of complex II: An evolutionary perspective

      2023, Biochimica et Biophysica Acta - Bioenergetics
      Citation Excerpt :

      Besides eukaryotes, these complexes are mainly present in Proteobacteria (Alphaproteobacteria, Betaproteobacteria, and Gammaproteobacteria) being also found within 20 % of unclassified bacterial genomes. Type D, to which E. coli FRD belongs [20,24,47,104–106], has a restricted taxonomic distribution when compared to type A or B. In Bacteria, with exception of Gammaproteobacteria where it is present in 30 % of 5777 metagenomic assemblies, type D is scarcely found across 17 phyla, such as Actinobacteria, Acidobacteria, Calditrichaeota, Bacteroidetes, Candidatus Marinimicrobia, Gemmatimonadetes, and Nitrospirae.

    • Catalytic mechanisms of complex II enzymes: A structural perspective

      2013, Biochimica et Biophysica Acta - Bioenergetics
    • Structural basis for malfunction in complex II

      2012, Journal of Biological Chemistry
      Citation Excerpt :

      These dicarboxylates can be either normal metabolic intermediates (18, 19, 29) or toxins (30). For example, fumarate, malate, oxaloacetate, and citrate are all Krebs cycle intermediates with a broad range of Ki values that may regulate complex II activity through feedback inhibition (18, 19). Each of these small molecules has been evaluated to determine the influence on the activity of the E. coli complex II homologs, and all act as either competitive or suicide inhibitors.

    • Geometric restraint drives on- and off-pathway catalysis by the Escherichia coli menaquinol:fumarate reductase

      2011, Journal of Biological Chemistry
      Citation Excerpt :

      For example, oxaloacetate is a Krebs cycle intermediate and acts as a tight, slow binding inhibitor of complex II, possibly as a regulatory mechanism (2, 3). It has additionally been proposed that oxaloacetate can be formed through off-pathway catalysis by complex II when fumarate hydration to malate is followed by oxidation to oxaloacetate (3, 4). Oxaloacetate binding to the complex II active site results in a charge transfer complex between the oxaloacetate carbonyl and the FAD hydride that can be monitored spectroscopically (4, 5).

    View all citing articles on Scopus

    This work was supported by National Institutes of Health Grant HL-16251, the Veterans Administration, and National Science Foundation Grant DMB-87-15560.

    View full text